Integra LifeSciences reported net income of $14.9 million for the third quarter of 2026, a significant recovery from a net loss of $5.4 million in the prior year period. Total revenue grew slightly to $411.2 million, while the company successfully reduced selling, general, and administrative expenses compared to 2025.
Integra LifeSciences reported Q3 2026 revenues of $411.2 million, a 2.3% increase year-over-year, despite a $7 million impact from flood damage at its Cincinnati facility. The company achieved GAAP net income of $14.9 million ($0.19 per share) and adjusted EPS of $0.59, while generating $96 million in operating cash flow.
Term
Q3 2026
“Our third quarter performance reflected mixed results across our portfolio, with stronger performance in Specialty Surgery partially offset by a $7 million impact from the Cincinnati disruption and softer-than-expected results in Tissue Reconstruction. We delivered results within our guidance ranges, generated strong cash flow, reduced leverage, and subsequently completed our debt refinancing.”
Stuart Essig, Chairman and Chief Executive Officer
“Our updated outlook reflects both the recovery timeline in Cincinnati and more measured expectations for portions of our Tissue Reconstruction business. We are focused on executing against these challenges while continuing to support our customers, advance key product launches and returns, and strengthen the business for more consistent long-term growth.”
Stuart Essig, Chairman and Chief Executive Officer
Integra Lifesciences Holdings $1.65B Debt Financing with Bank of America, N.A.
Integra LifeSciences completed a comprehensive refinancing of its debt, entering into a new $1.65 billion amended and restated credit agreement and issuing $450 million in 9.500% senior secured notes due 2033. The credit facility includes a $600 million revolver, a $600 million Term Loan A, and a $450 million Term Loan B. Proceeds were used to refinance the company's existing credit facility and pay related fees.